Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,055.96
(
-1.27%
)
News Focus
News Focus
Post# of 257579
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rkrw post# 65973

Tuesday, 09/09/2008 4:02:15 PM

Tuesday, September 09, 2008 4:02:15 PM

Post# of 257579
>BIOD – There actually is a lot of interest in the diabetes community for this…<

I guess I don’t see the attraction from a business standpoint of an enhanced formulation of a product—ordinary insulin—that is in a state of steady and irreversible decline.

What is the allure of BIOD’s reformulation (and similar products from other companies) versus an insulin analog or cocktail of analogs? T.i.a.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today